| Objective Through the clinical observation of Ai,di-injection combined with mFOLFOX6 chemotherapy in the treatment effect of advanced colorectal cancer patients,impact assessment to improve the quality of life after treatment and side effects,to further explore the effect of Ai,di-injection on chemotherapy in patients with advanced colorectal cancer,so as to provide the basis for clinical application.Methods 64 patients with advanced colorectal cancer in stage Ⅲ or Ⅳ,whose average age were(53.66±8.72),were selected from November 2015 to December 2016,including 35 cases in stage Ⅲ and 29 cases in stage Ⅳ,25 females and 39 males.Eligibility criteria were KPS score in more than 60 points,no contraindications to chemotherapy,almost normal blood routine,liver and renal function before chemotherapy.We randomly divided the 64 patients into the control group(32 cases)and the observation group(32 cases).There were no significant difference in age,sex and pathological type,pathological stage,KPS score and quality of life score between the two groups before treatment.The control group received only mFOLFOX6 chemotherapy(Oxaliplatin 85 mg/m2 IV over 2 hours,day 1;Leucovorin 400 mg/m2 IV over 2 hours,day 1;5-FU 400 mg/m2 IV bolus on day 1,then 1200 mg/m2/day * 2 days(total 2400 mg/m2 over 46-48 hours continuous infusion;Repeat every 14 days).The observation group received Ai’di-injection(50ml/d,intravenous drop infusion,synchronized with mFOLFOX6 chemotherapy)on the basis of the mFOLFOX6 chemotherapy.Two groups used the treatment of liver protection(glycyrrhizin),stomach protection(lansoprazole),antiemetic(tropisetron)and leukocyte enhancement(recombinant human granulocyte colony-stimulating factor).The quality of life scores,blood routine,liver and kidney function were evaluated before chemotherapy and after 3 weeks chemotherapy.The quality of life and adverse reactions were evaluated.The data were analyzed by SPSS22.0 software.Results 1.Comparison in quality of life improvement:(1)Comparison of the control group before and after the treatment: The scores of physical functioning(67.29±9.33)、Cognitive functioning(52.08±13.22)after treatment were lower than that(72.50±12.87、62.50±14.66)before treatment(P<0.05).The scores ofThe scores of pain(67.71±24.66)、Diarrhea(15.63±20.71)、Appetite loss(47.92±16.8)、Nausea and vomiting(34.9±7.76)after treatment were higher than that(53.13±16.63、6.25±13.22、27.08±13.22、11.46±14.32)before treatment(P<0.05).(2)Comparison of the observation group before and after the treatment: The scores of global health status(55.47±7.52)、Appetite loss(41.67±16.93)、 Nausea and vomiting(30.21±13.01)、Constipation(17.71±20.71)after treatment were higher than that(48.44±10.46、23.44±20.24、36.81±12.12、10.42±15.70)before the treatment(P<0.05).(3)Comparison of the two groups after the treatment: The scores of physical functioning(72.5±7.71)、 cognitive functioning(60.42±10.15)、global health status(55.47±7.52)after treatment were higher than that(67.29±9.33、52.08±13.22、48.96±8.13)before the treatment(P<0.05),The scores of fatigue(31.25±9.54)、constipation(56.25±17.84)after treatment were lower than that(38.54±8.92、67.71±24.66)before the treatment(P<0.05).2.Comparison of adverse reaction after the treatment:There were not renal function damage in the two groups.The occurrence rate of observation group was fewer than the control group in anemia(P<0.05).There was no difference between the observation group and the control group in the occurrence rate of leukopenia、 thrombocytopenia、liver function damage、hand foot reaction and neurotoxicity(P>0.05).Conclusion: Ai’di-injection combined with mFOLFOX6 chemotherapy in the treatment of advanced colorectal cancer,which can improve physical functioning、cognitive functioning、global health status,improve the quality of life,reduce adverse reactions,such as anemia. |
PDF Full Text Request